HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
Biohaven Pharmaceutical Holding Company Ltd. +2.55%
Biohaven Pharmaceutical Holding Company Ltd. BHVN | 52.65 | +2.55% |
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:
BHVN) with a Buy and maintains $59 price target.